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“We must seriously think about proceeding further than
looking for cures just for rodents”. These ironic words
were recently pronounced in a public forum by a medi-
cal doctor devoted to basic research, who decided to
move from experimentation in rat arteries to human
vessels in her search for new targets for cardiovascular
diseases. Scientists dealing with basic neuropsychiatric
research must seriously examine this question and
another one even more critical: are we looking for cures
for diseases in biological systems not willing to suffer
them in nature? In other words: can we consider spon-
taneous dementia, anorexia nervosa, addiction or schizo-
phrenia specific human diseases? If so... is it intelligent
trying to progress in the knowledge of these pathologies
on the basis of home-made, artificial animal models?
Must we persist on this way or center exclusively on
human experimentation?
The bench to bedside two-way travel is always proble-
matic, but it appears especially difficult when dealing
with neuropsychiatric disorders where psychosocial vari-
ables seem to play an essential role, both in the emer-
gence and maintenance of the problem. This fact
extremely complicates laboratory modeling. It is clear
that the fast development of the neurosciences along the
XX century has led to important medical progress,
enabling therapists to use modern, advanced tools (i.e.,
rationale-based designed drugs instead of serendipity-
based old remedies). However, a significant gap still per-
sists between basic science and medical applications for
the patients, in part due to the shortage (sometimes
absence) of preclinical models with enough face, con-
struct and predictive validity. This may explain why we
keep unable to find ways to defeat old, classical barriers,
i.e. the widely known 3/4-w e e kl a p s ef o rt h eo n s e to f
antidepressant actions or the persisting 30% of patients
still refractory to the available antidepressants. Finding
new ways to overcome this bottleneck seems therefore a
major challenge for neuroscientists.
When significant advances are finally achieved in basic
science, and even in the case that they look promising in
randomized clinical trials, prominent barriers still remain
to prevent fast translations into clinical practice. These are
the targets of the so-called T2 translational research, as
defined by the American Institute of Medicine’s Clinical
Research Roundtable. T2 research deals with problems
such as cost-effectiveness and feasibility of implementation
in health care systems. The need for promoting T2 research
and its coupling with new developments from basic neu-
roscience has been recently qualified as “urgent” by NIMH
investigators working on psychotic disorders, especially
worried about the outcome of extremely vulnerable popula-
tions. Besides psychiatrists, neurologists have also expressed
the opportunity of encouraging all the steps of translational
research from basic science to the clinics and backwards, a
process which is expected to render promising results in
prioritized research areas (stroke, headache, multiple
sclerosis, epilepsy and dementias, in the case of the US).
Translational research on neuropsychiatric disorders is
less developed than in other areas (i.e. oncology), but it is
an emerging issue. Any new tool for the dissemination of
results in the field can greatly help to progress in the
achievement of new solutions for the neuropsychiatric
patient, and this is the main goal of the new Neuros-
ciences Section of the Journal of Translational Medicine.
We hope to encourage publications and promote the
increase of knowledge on the subject by collecting origi-
nal articles together in this new specific section.
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